Results 221 to 230 of about 2,148,890 (355)
An extensive direct assay in biological assay
The ordinary method of the biological direct assay has been described by many authors and most investigators being engaged in the biological assay have practiced the method for a long time. It seems, however, to us that the method is in need of large number of subjects and the fiducial limits appling Fieller's theorem are mostly too wide to be useful ...
openaire
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Correction: Bioproduction, characterization, anticancer and antioxidant activities of extracellular melanin pigment produced by newly isolated microbial cell factories Streptomyces glaucescens NEAE-H. [PDF]
El-Naggar NE, El-Ewasy SM.
europepmc +1 more source
Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed +10 more
wiley +1 more source
Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection of <i>IDH</i> Variants in Solid Tumors and Hematological Malignancies. [PDF]
Gilson P +10 more
europepmc +1 more source

